Vaxxel: Funding, Investors & Team (Sep 2026)
Vaxxel is an Innovative viral live-attenuated platform that develops novel and proprietary live-attenuated vaccine candidates against bronchiolitis and pneumonia caused by pneumovirus.
Vaxxel has raised $1.3M across 1 funding round on record, the most recent a Seed of $1.3M announced in Mar 2022.
That round is below the $5.0M median round size for Health Care companies tracked on FundedIQ over the last two years.
Vaxxel Company Profile and Key Stats
Latest funding round on record: Mar 2022.
Vaxxel Funding Rounds
Vaxxel Founders and Leadership Team
No contact details are on record for this team yet.
Vaxxel Funding Compared to Other Health Care Startups
Vaxxel's latest round of $1.3M is below the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Vaxxel in Health Care and Villeurbanne
Companies Similar to Vaxxel
Implicity is a developer of a Saas-based remote monitoring platform designed to provide smart monitoring of…
Beams is a producer of medical devices for cancerology based on the use of particles β.
Padoa is an occupational health software firm that develops a tool for monitoring the health of employees.…
CILcare specializes in providing drug solutions for hearing and ear disorders.
MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials,…
noa is a digital fitness and wellness company that offers premium, structured training programs for strength,…
Semeia offers patient monitoring solution designed to support medical followup of patients, remotely and in…
Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the…
Axomove is an e-wellbeing application that spends significant time in video actual activities.
Parallel helps coding agent works side by side with hospital teams to deliver faster and more accurate…
May Health has created a new solution for infertility caused by Polycystic Ovary Syndrome (PCOS) that is…
MedinCell is an injectable slow-release drug specialist company.
Vaxxel Funding FAQs
What does Vaxxel do?
Vaxxel is an Innovative viral live-attenuated platform that develops novel and proprietary live-attenuated vaccine candidates against bronchiolitis and pneumonia caused by pneumovirus.
How much funding has Vaxxel raised?
Vaxxel has raised $1.3M across 1 round on record. The most recent is a Seed of $1.3M announced in Mar 2022.
When did Vaxxel last raise funding?
Vaxxel's most recent funding round on record is a Seed of $1.3M, announced in Mar 2022.
Who is the CEO of Vaxxel?
Denis Cavert is listed as CEO at Vaxxel.
Where is Vaxxel headquartered?
Vaxxel is based in Villeurbanne, Rhone-Alpes, France.
How many employees does Vaxxel have?
Vaxxel is in the 1-10 employee band.
How does Vaxxel's funding compare to other Health Care startups?
Vaxxel's latest round of $1.3M is below the $5.0M median round size for Health Care companies on FundedIQ across 3,654 tracked companies over the last two years.
About FundedIQ's Vaxxel Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Vaxxel is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.